

WHO IS BOSTON HEART DIAGNOSTICS?



At a glance:

- Boston Heart Diagnostics was founded in 2007 and originally operated under the name Boston Heart Lab. The company was founded by scientists Dr. Ernst Schaefer and Dr. Bela Asztalos.
- Headquartered in Framingham, Massachusetts, Boston Heart Diagnostics was purchased by Eurofins Scientific, a \$2 billion global healthcare organization, in January 2015.
- Boston Heart Diagnostics' laboratory is CAP-certified and CLIA-accredited with state of the art equipment that specializes in a wide range of laboratory techniques, including gas chromatography, gel electrophoresis, genetic and molecular testing, general chemistry, immunoassay, and high performance liquid chromatography.
- Boston Heart Diagnostics is licensed to test in all 50 states.



What does Boston Heart offer?

- A focused and relevant test menu which helps characterize disease and inform treatment decisions. Our test menu ranges from routine tests to complex and specialized in the areas of lipids, inflammation, metabolics and genetics.
- We provide clinicians and patients with industry leading, patient-centric reports completely personalized to the individual. Our reports can enhance patient engagement and education by explaining test results and treatment considerations in patient friendly language.
- We publish original research in peer reviewed publications and at medical and scientific conferences. Boston Heart supplements this research with a team of Medical Science Liaisons, who provide medical education via clinician consults in a variety of settings and provide summaries of our research via a quarterly clinician newsletter.



How does Boston Heart help improve patients' health?

- We offer a scientifically designed Lifestyle Program, which integrates test results, patient history, and food likes and dislikes to create a Personalized Nutrition and Life Plan tailored to the patient.
- We have expert support from Registered Dietitians available to help drive accountability and adherence to treatment plans.
- We have partnered with the Centers for Disease Control and Prevention (CDC)* to offer a proven and effective lifestyle change program for patients who have prediabetes or are at risk of developing type 2 diabetes to help patients prevent or delay type 2 diabetes.

Company Overview

Boston Heart Diagnostics recognizes that cardiovascular disease (CVD) and diabetes are complex and every patient's story is different—patient care needs to be individualized if we are to make a significant impact on clinical outcomes.

Boston Heart Diagnostics is transforming the treatment by integrating test results with patient history to create highly personalized laboratory reports that provide healthcare providers with a comprehensive picture of a patient's health.

Boston Heart employees have a singularly focused mission:

Partner with healthcare providers to enable everyone to improve health and prevent disease.

bostonheart
diagnostics®

It is difficult to predict if a patient will have a cardiovascular event.

“A majority of middle-aged patients who experienced a first myocardial infarction (MI) had a traditional risk factor profile which would not have qualified them for preventive medical therapy.”¹

Why Boston Heart’s advanced testing can be beneficial:

- The standard lipid panel has not been updated for over 30 years.
- Current available methods for estimating cardiovascular risk often underestimate risk especially in patients at intermediate risk.³
- Research shows that following current treatment guidelines reduces a patient’s residual risk for cardiovascular events by only 25%—meaning that standard therapy fails to address 75% of a patient’s remaining residual risk for cardiovascular events.⁵
- Approximately 50% of patients having heart attacks or strokes have normal lipid levels.²
- According to the American Heart Association, for many Americans, their first symptom of cardiovascular disease is a heart attack or sudden death.⁴
- Statins only reduce CVD risk when taken. 42% of patients stop taking statin medication within six months of beginning treatment and 58% of patients stop taking statin medication within 1 year.⁶

Visit www.bostonheartdiagnostics.com or call 877.425.1252, option 4 for more information.

*Boston Heart has received pending recognition as a provider of the Centers for Disease Control and Prevention’s (CDC) National Diabetes Prevention Program (NDPP).

References:

1. Akosah KO, Schaper A, Cogbill C. Preventing myocardial infarction in the young adult in the first place: how do the National Cholesterol Education Panel III guidelines perform? J Am Coll Cardiol. 2003;41(9):1475-1479.
2. Sachdeva A, Cannon CP, Deedwania PC, et al. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines. Am Heart J. 2009;157:111-117.e2.
3. Toth P et al. Lipoprotein-associated phospholipase A2: Role in atherosclerosis and utility as a cardiovascular biomarker. Expert Rev Cardiovasc Ther. 2010; 8:425-438.
4. Go AS, Mozaffarian D, Roger VL, et al. Heart Disease and Stroke Statistics—2013 Update: A Report From the American Heart Association. Circulation. 2013;127:143- 152.
5. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–1504.
6. Davidson MH, Sun SX, Nag SS, et al. Risk factors for discontinuation of statin medications: evidence from a large national pharmacy claims database. Circulation. 2007;116 (16 suppl):II-847. Abstract 3726.

877.425.1252 bostonheartdiagnostics.com   

©2018 Boston Heart Diagnostics Corporation. All rights reserved. The Boston Heart logo is a registered trademark of Boston Heart Diagnostics Corporation in the U.S. and in other countries. Boston Heart Diagnostics Corporation reserves the right to change this document at any time without notice and disclaims liability for editorial, pictorial or typographical errors.

04310118

bostonheart
diagnostics®